Effects of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: Results of theLEADERandSUSTAIN6 trials Article

Industry Collaboration International Collaboration

cited authors

  • Verma, Subodh; McGuire, Darren K.; Bain, Stephen C.; Bhatt, Deepak L.; Leiter, Lawrence A.; Mazer, C. David; Monk Fries, Tea; Pratley, Richard E.; Rasmussen, Soren; Vrazic, Hrvoje; Zinman, Bernard; Buse, John B.

authors

Publication Date

  • September 4, 2020

webpage

published in

category

keywords

  • body mass index
  • cardiovascular
  • liraglutide
  • major adverse cardiovascular events
  • semaglutide

start page

  • 2487

end page

  • 2492

volume

  • 22

issue

  • 12